Skip to main content

Advertisement

Table 1 Baseline characteristics of the whole cohort and divided by responder status

From: Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

Characteristic Data availability All patients (n = 1050) Responders (n = 601) Non-responders (n = 449)
Demographic and lifestyle factors
 Female sex 1050 (100) 707 (67) 398 (66) 309 (69)
 Age (years) 1050 (100) 59 (49, 68) 60 (49, 68) 58 (48, 67)
 BMI (kg/m2) 959 (91) 27.5 (24.2, 31.6) 27.4 (24.1, 31.1) 27.9 (24.3, 33.0)
 Smoking: never 1042 (99) 420 (40) 260 (44) 160 (36)
 Smoking: former 404 (39) 232 (39) 172 (39)
 Smoking: current 218 (21) 104 (17) 114 (26)
 Alcohol consumption: current 1030 (98) 710 (69) 401 (68) 309 (71)
 Alcohol consumption: (units/fortnight) 1009 (96) 2 (0, 10) 2 (0, 10) 2 (0, 12)
 Coffee/tea consumption: (cups/day) 815 (78) 4 (3, 6) 4 (2, 6) 4 (3, 6)
 IMD score 990 (94) 13.9 (8.9, 24.5) 13.7 (8.5, 23.7) 14.8 (9.5, 27.2)
Disease-specific factors
 Symptom duration (months) 1042 (99) 9 (4, 28) 8 (4, 24) 10 (4, 33)
 RF positive 889 (85) 584 (66) 354 (70) 230 (60)
 Satisfied the 1987 ACR criteria 962 (92) 787 (82) 470 (85) 317 (77)
 HAQ score 989 (94) 1.1 (0.5, 1.6) 1.1 (0.5, 1.8) 1.0 (0.4, 1.5)
 Co-morbidities: 0 1050 (100) 392 (37) 240 (40) 152 (34)
 Co-morbidities: 1 345 (33) 189 (31) 156 (35)
 Co-morbidities: 2+ 313 (30) 172 (29) 141 (31)
 Creatinine (mg/dl) 970 (92) 67 (59, 77) 66 (58, 76) 67 (60, 79)
Disease activity
 Morning stiffness (minutes) 1000 (95) 60 (15, 120) 60 (20, 120) 60 (10, 90)
 TJC28 1050 (100) 6 (2, 13) 8 (4, 15) 4 (1, 10)
 SJC28 1050 (100) 5 (2, 10) 6 (3, 12) 3 (1, 7)
 CRP (mg/l) 1050 (100) 5.6 (2.0, 16.2) 8.2 (2.8, 21.4) 3.8 (1.5, 9.9)
 Patient VAS (mm) 1050 (100) 41 (23, 60) 47 (26, 66) 32 (19, 50)
 DAS28-CRP 1050 (100) 4.3 (3.3, 5.3) 4.7 (3.9, 5.7) 3.7 (2.8, 4.6)
 DAS28-CRP ≤ 3.2 1050 (100) 226 (22) 64 (11) 162 (36)
 DAS28-CRP ≤ 2.6 1050 (100) 102 (10) 12 (2) 90 (20)
 Pain VAS (mm) 971 (92) 50 (28, 71) 53 (30, 73) 46 (25, 68)
 Fatigue VAS (mm) 974 (93) 54 (27, 73) 54 (28, 74) 53 (27, 72)
Medication
 Oral steroids: current 1048 (100) 210 (20) 119 (20) 91 (20)
 Intramuscular steroids: recent 1028 (98) 234 (23) 137 (23) 97 (22)
 Intra-articular steroids: recent 882 (84) 27 (3) 14 (3) 13 (3)
 Oral or intramuscular steroids: current/recent 1031 (98) 423 (41) 244 (41) 179 (40)
 NSAIDs: current 942 (90) 520 (55) 296 (55) 224 (55)
 csDMARDs: current 1050 (100) 193 (18) 100 (17) 93 (21)
 csDMARDs: ever 1050 (100) 238 (23) 120 (20) 118 (26)
 MTX starting dose (mg/week) 1042 (99) 10 (10, 15) 10 (10, 15) 10 (10, 15)
Psychosocial factors
 HADS anxiety 986 (94) 6 (3, 9) 6 (3, 9) 6 (3, 10)
 HADS depression 987 (94) 6 (3, 9) 6 (3, 9) 5 (2, 8)
 BMQ medication necessity 942 (90) 19 (17, 22) 20 (17, 23) 19 (17, 22)
 BMQ medication concerns 949 (90) 15 (13, 18) 15 (12, 17) 16 (13, 18)
 BMQ necessity-concerns 923 (88) 4 (1, 8) 5 (1, 8) 4 (1, 8)
 IPQ negative illness representation 967 (92) 560 (58) 330 (59) 230 (56)
  1. Values are frequency (%) or median (IQR)
  2. Abbreviations: BMI body mass index, IMD Index of Multiple Deprivation, RF rheumatoid factor, HAQ Health Assessment Questionnaire, TJC28 tender 28-joint count, SJC28 swollen 28-joint count, CRP C-reactive protein, VAS visual analogue scale, DAS28 Disease Activity Score based on the 28-joint count, NSAIDs non-steroidal anti-inflammatory drugs, csDMARDS conventional synthetic disease-modifying anti-rheumatic drugs, HADS Hospital Anxiety and Depression Scale, BMQ Beliefs about Medicines Questionnaire, IPQ Illness Perception Questionnaire